Takeover Target, page-2

its very undervalued but i doubt it is a t/o target enough hanging over their head in the way of external risks (doj, customer consolidation, healthcare reform) that they cant control or fix to make the pe t/o groups wary, and the big players in generics eg teva and allergan are too indebted to look at and industry takeover of a smaller player like myx. its still around a bill in market cap so a big investment.
also large short position is a potential disincentive that could drive prices up rapidly in a squeeze pre t/o.

perhaps im a tad biased as ive reduced my holdings at a loss and am looking to buy back in in around 2 months once the sp has stabilised but before the fy end result, so just my opinion on the matter.